BCX 140

Drug Profile

BCX 140

Latest Information Update: 03 Oct 2001

Price : $50

At a glance

  • Originator BioCryst Pharmaceuticals; University of Alabama
  • Class Antivirals
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 03 Oct 2001 Discontinued-Preclinical for Influenza virus infections in USA (Unknown route)
  • 07 May 2001 Ortho-McNeil and RW Johnson have given 4 months' notice that they intend to terminate their license
  • 16 Feb 2001 Profile reviewed but no significant changes made
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top